Gen-Wealth Partners’s Beam Therapeutics BEAM Stock Holding History

Gen-Wealth Partners’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$618	Hold	18	–	–	﹤0.01%	687
2026 Q1	$429	Hold	18	–	–	﹤0.01%	698
2025 Q4	$499	Hold	18	–	–	﹤0.01%	661
2025 Q3	$437	Hold	18	–	–	﹤0.01%	659
2025 Q2	$306	Hold	18	–	–	﹤0.01%	625
2025 Q1	$352	Hold	18	–	–	﹤0.01%	591
2024 Q4	$446	Hold	18	–	–	﹤0.01%	623
2024 Q3	$405	Hold	18	–	–	﹤0.01%	638
2024 Q2	$422	Hold	18	–	–	﹤0.01%	623
2024 Q1	$595	Buy	+18	New	+$561	﹤0.01%	602

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Gen-Wealth Partners's BEAM Position: Q2 2026 in Review

Gen-Wealth Partners held its Beam Therapeutics (BEAM) position steady in Q2 2026 at 18 shares worth $618. The position accounts for ﹤0.01% of the portfolio, ranked #687.

Gen-Wealth Partners first reported a position in BEAM in Q1 2024 and has held it in 10 quarters since. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Gen-Wealth Partners held 18 shares of Beam Therapeutics worth $618 as of Q2 2026.
Gen-Wealth Partners left its Beam Therapeutics share count unchanged in Q2 2026.
Beam Therapeutics made up ﹤0.01% of Gen-Wealth Partners's portfolio in Q2 2026, its #687 holding.
Gen-Wealth Partners first reported a position in Beam Therapeutics in Q1 2024 and has held it in 10 quarters since.
278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Gen-Wealth Partners's 13F filing for Q2 2026, filed 10 Aug 2026.